Abstract
Cannabidiol (CBD) is gaining considerable attention in the research community with promising results in a variety of neuropsychiatric conditions. In particular, there are replicated findings for the therapeutic effects of CBD on psychotic and anxiety symptoms as well as substance use disorders, all of which are highly prevalent in patients who present with suicidality. Meanwhile, there has been a lack of suicide research on cannabidiol. This perspective provides an overview of the available evidence, potential reasons behind the halt in suicide research on cannabidiol, and recommendations for future investigations.
Keywords: Cannabidiol, cannabis, marijuana, suicide, adverse events, psychopharmacology.
Graphical Abstract
Related Journals
Current Drug Safety
Current Pharmaceutical Design
Current Neurovascular Research
Current Pharmaceutical Analysis
Central Nervous System Agents in Medicinal Chemistry
Current Vascular Pharmacology
Current Alzheimer Research
CNS & Neurological Disorders - Drug Targets
Current Molecular Pharmacology
Current Aging Science
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Frontiers in Clinical Drug Research-Dementia
9